Alnylam Pharmaceuticals said this week that it has granted partner Tekmira Pharmaceuticals a new license to use its intellectual property to discover, develop, and commercialize an RNAi therapeutic for the treatment of Ebola virus infection.
Under the deal, Alnylam stands to receive royalties on sales of products developed using the licensed technology. Additional terms were not disclosed.
Tekmira is developing an siRNA-based Ebola therapeutic called TKM-EBOLA, which it expects to advance to the investigational new drug application-filing stage in the second half of 2011.
Earlier this year, the company received a contract worth up to $140 million from the US Department of Defense Chemical and Biological Defense Program to develop the drug (GSN 8/19/2010).
Separately, the company received a $2.4 million grant from the National Institutes of Health to develop RNAi therapeutics against Ebola and Marburg hemorrhagic fever viral infections.